Bardet–Biedl syndrome: when the appetite receptor can't reach its antenna

Not a missing signal this time, but a signal with nowhere to land — the appetite receptor stranded short of the antenna it was built to stand on.

Most of the melanocortin obesity conditions break the appetite circuit by removing a part of it — the precursor or its receptor. Bardet–Biedl syndrome breaks it in a stranger, more revealing way: everything is present, but the receptors that read the appetite signal cannot get to the place they are supposed to work. It is a melanocortin disease by a back door, and following that back door turns out to explain a great deal.^[2]

A disease of the cell's antenna

BBS is what doctors call a ciliopathy. Nearly every cell in the body carries a single primary cilium — a slender, antenna-like projection it uses to sense its surroundings and receive signals. BBS is caused by mutations in a set of genes (more than twenty are now known) that build a protein machine called theBBSome, whose job is to traffic specific receptors out to that antenna and manage what sits on it.^[2] Because cilia are everywhere, the damage is everywhere: the light-sensing cells of the retina degenerate, causing progressive sight loss; the kidneys, limbs, and reproductive system develop abnormally; and the appetite system misfires. The classic features include rod–cone retinal dystrophy, obesity, postaxial polydactyly (extra fingers or toes), kidney anomalies, hypogonadism, and learning difficulties.^[2]

Why the antenna matters for appetite

Here is the connection to this site. The appetite neurons of the hypothalamus do not read leptin and melanocortin signals from just anywhere on their surface — the relevant receptors, including the machinery of the MC4R appetite pathway, need to be positioned on the primary cilium to work properly. The BBSome is what ferries them there. When the BBSome is faulty, those receptors never reach the antenna; they are left stranded in the cell body, and the leptin–melanocortin signal that should restrain hunger is simply not received.^[2]

So the break in BBS is subtly different from the one in POMC deficiency, and the difference is worth holding onto. In POMC deficiency the signal is missing. In BBS the signal is made and released, but there is no properly placed receiver. Both roads arrive at the same destination: an MC4R pathway that is not being driven, and an appetite with no brake.

The treatment, and what it reaches

Because the problem ends at an under-driven MC4R, a drug that drives MC4R directly can help — regardless of why the receptor is quiet. Setmelanotide, the MC4R agonist, re-supplies the appetite signal downstream of the ciliary defect. In a Phase 3 randomised, placebo-controlled trial in people with BBS, it produced meaningful weight loss and reductions in hunger, and on that basis the FDA approved it for Bardet–Biedl syndrome in2022 — its second major indication after the POMC and leptin-receptor deficiencies.^[1][3]

The limit is as important as the result. Setmelanotide treats the obesity and the hunger of BBS; it does nothing for the retinal degeneration, the kidney disease, or the other consequences of broken cilia, which are managed separately. It is a targeted fix for the one arm of a many-armed syndrome that happens to run through the melanocortin system.^[1]

The honest bottom line

Bardet–Biedl syndrome earns its place here because it widens the definition of a "melanocortin disease." You do not have to delete the signal or its receptor to break the appetite circuit — you only have to stop the receptor from reaching the antenna where it listens. That the same drug helps across POMC deficiency, leptin-receptor deficiency, and a ciliopathy is the strongest evidence that MC4R is the true common chokepoint of human appetite. For the drug, see setmelanotide; for the receptor, see MC4R; for the conditions it shares a mechanism with, see POMC & leptin-receptor deficiency and hypothalamic obesity.